Document Detail


High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort.
MedLine Citation:
PMID:  12478325     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The purpose of this study was to recognize nucleoside reverse transcriptase inhibitor (NRTI)-resistant HIV-1 strains among a group of therapy-naive patients, and subsequently to guide the choice of antiretroviral therapy. PATIENTS AND METHODS: HIV strains present in sera of 128 antiretroviral therapy-naive patients were tested for NRTI resistance-associated mutations. The RT-PCR amplified HIV rt regions were analyzed with an INNI-LiPA-HIV-1 RT assay. The number and pattern of resistance-associated mutated codons were determined and interpreted as resistance to particular drugs. RESULTS: Mutated codons were detected in 66 (51.5%) out of 128 tested samples. In 54 (81.8%) out of 66 samples, a K70R mutation was identified, which was followed by an M184V mutation in 22 cases (33.3%). For a majority of these samples, mixed wild/mutant populations were recognized in 44 (66.6%) cases. The interpretation of hybridization data revealed drug-resistant strains in 37 (28.9%) out of all samples tested. The determined resistance to particular drugs was as follows: 20 strains were resistant to zidovudine (ZDV), ten to lamivudine (3TC) and six to didanosine (ddI)/zalcitabine (ddC)/abacavir (ABC). In one case, a ZDV/3TC-resistant HIV strain was found. CONCLUSION: The prevalence of mutations associated with NRTI resistance was high in the tested cohort. The key reasons for that were most probably needle and drug sharing within the group of intravenous drug users (IVDUs) and the use of ZDV in monotherapeutic regimes in the early 1990s.
Authors:
A Horban; J J Stanczak; E Bakowska; E J Tobolewska; K J Przybylska-Stengiel; G P Stanczak; E Burkacka
Related Documents :
20145735 - Mode of antiviral action of silver nanoparticles against hiv-1.
17935165 - Successful treatment of an entecavir-resistant hepatitis b virus variant.
16641095 - Persistence of nevirapine-resistant hiv-1 in women after single-dose nevirapine therapy...
10682135 - Diminished hiv-1 sensitivity to stavudine in patients on prolonged therapy occurs only ...
15287585 - The trypanosoma brucei reference strain treu927/4 contains t. brucei rhodesiense-specif...
7680425 - Characterization of stable high molecular weight mutagenic product(s) of plant-activate...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Infection     Volume:  30     ISSN:  0300-8126     ISO Abbreviation:  Infection     Publication Date:  2002 Dec 
Date Detail:
Created Date:  2002-12-12     Completed Date:  2003-02-20     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0365307     Medline TA:  Infection     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  356-9     Citation Subset:  IM    
Affiliation:
Molecular Diagnostic Laboratory, AIDS Diagnosis and Therapy Center, Hospital for Infectious Diseases, 37 Wolska Str., PL-01-201 Warsaw, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acquired Immunodeficiency Syndrome / drug therapy*,  virology
Adult
Anti-HIV Agents / therapeutic use*
Cohort Studies
Drug Resistance, Viral
Genotype
HIV Reverse Transcriptase / genetics*
HIV-1 / drug effects*,  genetics
Humans
Lamivudine / therapeutic use
Middle Aged
Mutation
Reverse Transcriptase Inhibitors / therapeutic use*
Zidovudine / therapeutic use
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Reverse Transcriptase Inhibitors; 134678-17-4/Lamivudine; 30516-87-1/Zidovudine; EC 2.7.7.49/HIV Reverse Transcriptase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Surveillance of measles-mumps-rubella vaccine-associated aseptic meningitis in Germany.
Next Document:  Analysis of T-cell receptor V-beta 2 in peripheral blood lymphocytes as a diagnostic marker for Kawa...